Health Bulletin 01/July/2023

Here are the top health stories for the day:

AIIMS Delhi plans to lease hostels near institute for students, resident doctors

Aiming to significantly alleviate the challenges faced by students and resident doctors and provide them with a secure and conducive living environment, the All India Institute of Medical Sciences (AIIMS) Delhi has decided to float an expression of interest by July 31 to explore the option of leasing fully furnished hostel accommodations nearer to the premier institute or at a reasonable distance with good connectivity by Delhi Metro.

The decision is taken to prioritize the welfare and safety of its students and resident doctors.

The authorities have been meeting undergraduate, postgraduate, PhD students studying at AIIMS New Delhi and it was noted that one of the major hardships faced by them is searching for alternate accommodation near AIIMS while awaiting allotment of official hostel accommodation.

For more details, check out the link given below:

AIIMS Delhi To Lease Hostels Near Institute, More Than 3,000 Medical Students, Resident Doctors To Benefit

First Skin Bank established at AIIMS in Delhi, to benefit burnt patients

In a bid to provide relief to burn injury patients, the premier health institution, the All India Institute Of Medical Sciences (AIIMS) Delhi, opened its first skin bank after the Safdurjung Hospital inaugurated the facility a week ago.

The first Skin Bank was inaugurated at the All India Institute Of Medical Sciences (AIIMS) Hospital on Thursday in New Delhi which will benefit burn patients.

According to the officials, a skin-bank skin bank manual was also released to provide a new lease of life to burn patients. This bank with technologically advanced machines will be of great help in saving the lives of severe burn patients.

For more details, check out the link given below:

Delhi AIIMS Opens Second Skin Bank After Safdurjung Hospital

Rs 1000 to Rs 2000 for NExT mock test: Doctors, students slam NMC for charging huge fees

The medical fraternity is upset over the decision of the authorities to charge Rs 1000 to Rs 2000 fees for appearing in the mock test of the National Exit Test (NExT).

Medical Dialogues had earlier reported that after addressing apprehensions regarding the conduction of NExT, NMC released the information brochure for the mock/practice test of the NExT exam. The test is going to be conducted by the All India Institute of Medical Sciences (AIIMS).

According to the Information Brochure, the Mock Test is going to be conducted on July 28, 2023, and the registration for this started on 28th June. The application fee for the test is Rs 2,000 for the candidates belonging to the General and OBC Categories. For the applicants belonging to SC, ST, and EWS categories, the application fee is Rs 1,000. Persons with Disabilities are not being charged any fees for appearing in the mock test.

For more details, check out the link given below:

Rs 1000 To Rs 2000 For NExT Mock Test: Doctors, Students Slam NMC For Charging Huge Fees

Drug safety alert: Indian Pharmacopoeia Commission flags adverse reactions linked to Teneligliptin

The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of June, has revealed that the popular antidiabetic drug Teneligliptin is linked with adverse drug reactions (ADRs) named Bullous Pemphigoid.

This came after a preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.

Teneligliptin is a recently developed oral dipeptidyl peptidase 4 inhibitor indicated for the management of type 2 diabetes mellitus (T2DM) in adults along with diet and exercise. The mechanism of Teneligliptin is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.

For more details, check out the link given below:

Drug Safety Alert: Indian Pharmacopoeia Commission Flags Adverse Reactions Linked To Teneligliptin